Skip to content
Boca Raton City Online – Lifestyle
Author:
FibroBiologics, Inc.
FibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot Ulcers
June 16, 2026
FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers
June 3, 2026
FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting
May 22, 2026
FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics
May 18, 2026
Hagerty Reports First Quarter 2026 Results; Reaffirms 2026 Growth Outlook
May 16, 2026
FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus
May 11, 2026
FibroBiologics CEO Issues Letter to Shareholders
May 5, 2026
FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring
May 4, 2026
FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
May 4, 2026
FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update
April 30, 2026
1
2
3
Next Page
→